Article
Gag mutations strongly contribute to HIV-1 resistance to protease inhibitors in highly drug-experienced patients besides compensating for fitness loss.
PLoS pathogens - 1 Mar 2009
Dam Elisabeth, Quercia Romina, Glass Bärbel, Descamps Diane, Launay Odile, Duval Xavier, Kräusslich Hans-Georg, Hance Allan J, Clavel François
Abstract excerpt
Human immunodeficiency virus type 1 (HIV-1) resistance to protease inhibitors (PI) results from mutations in the viral protease (PR) that reduce PI binding but also decrease viral replicative capacity (RC). Additional mutations compensating for the RC loss subsequently accumulate within PR and in Gag substrate cleavage sites. We examined the respective contribution of mutations in PR and Gag to PI resistance and...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
